keyword
MENU ▼
Read by QxMD icon Read
search

Mirabegron

keyword
https://www.readbyqxmd.com/read/28228331/-efficacy-and-safety-of-available-therapies-in-the-management-of-idiopathic-overactive-bladder-a-systematic-review-of-the-literature
#1
J Moyson, F Legrand, M Vanden Bossche, T Quackels, T Roumeguère
OBJECTIVE: Study the efficacy and adverse events of different pharmacological lines in the treatment of idiopathic overactive bladder (iOAB). METHODS: PubMed research on meta-analyses and randomized controlled trials (RCT) focused on the efficacy and adverse effects of anticholinergics, botulinum toxin and mirabegron since 2005. RESULTS: Ten meta-analyses of anticholinergics were selected; 16 randomized controlled trials (ERC) comparing botulinum toxin A to either anticholinergic or placebo and 10 ERC studying mirabegron...
February 19, 2017: Progrès en Urologie
https://www.readbyqxmd.com/read/28220521/indirect-treatment-comparison-itc-of-medical-therapies-for-an-overactive-bladder
#2
Aneta Obloza, Joshua Kirby, Derrick Yates, Philip Toozs-Hobson
BACKGROUND: Overactive bladder syndrome (OAB) is a chronic and prevalent condition which has a negative impact on Quality of Life. The National Institute of Clinical Excellence issued two documents which give slightly varying algorithms of pharmacotherapy for OAB, offering mirabegron as a possible treatment in certain circumstances. In the absence of trials involving a direct comparison of therapies, an indirect comparison can provide useful information on the difference in treatment effects between competing interventions...
February 21, 2017: Neurourology and Urodynamics
https://www.readbyqxmd.com/read/28208559/re-mirabegron-causes-relaxation-of-human-and-rat-corpus-cavernosum-could-it-be-a-potential-therapy-for-erectile-dysfunction
#3
Allen D Seftel
No abstract text is available yet for this article.
March 2017: Journal of Urology
https://www.readbyqxmd.com/read/28208543/re-efficacy-and-safety-of-mirabegron-add-on-therapy-to-solifenacin-in-incontinent-overactive-bladder-patients-with-an-inadequate-response-to-initial-4-week-solifenacin-monotherapy-a-randomised-double-blind-multicentre-phase-3b-study-beside
#4
https://www.readbyqxmd.com/read/28208541/re-mirabegron-relaxes-urethral-smooth-muscle-by-a-dual-mechanism-involving-%C3%AE-3-adrenoceptor-activation-and-%C3%AE-1-adrenoceptor-blockade
#5
Alan J Wein
No abstract text is available yet for this article.
March 2017: Journal of Urology
https://www.readbyqxmd.com/read/28196724/persistence-and-adherence-with-mirabegron-versus-antimuscarinic-agents-in-patients-with-overactive-bladder-a-retrospective-observational-study-in-uk-clinical-practice
#6
Christopher R Chapple, Jameel Nazir, Zalmai Hakimi, Sally Bowditch, Francis Fatoye, Florent Guelfucci, Amine Khemiri, Emad Siddiqui, Adrian Wagg
BACKGROUND: Persistence with antimuscarinic therapy in overactive bladder (OAB) is poor, but may be different for mirabegron, a β3-adrenoceptor agonist with a different adverse event profile. OBJECTIVE: To compare persistence and adherence with mirabegron versus tolterodine extended release (ER) and other antimuscarinics in routine clinical practice over a 12-mo period. DESIGN, SETTING, AND PARTICIPANTS: Retrospective, longitudinal, observational study of anonymised data from the UK Clinical Practice Research Datalink GOLD database...
February 11, 2017: European Urology
https://www.readbyqxmd.com/read/28120446/phase-iii-study-to-assess-long-term-52-week-safety-and-efficacy-of-mirabegron-a-%C3%AE-3-adrenoceptor-agonist-in-japanese-patients-with-overactive-bladder
#7
Osamu Yamaguchi, Yasushi Ikeda, Sumito Ohkawa
OBJECTIVES: To investigate safety, tolerability and efficacy of long-term (52 weeks) open-label treatment with mirabegron 50 mg, with an optional dose increase to 100 mg, in patients with overactive bladder (OAB). METHODS: Patients received mirabegron 50 mg once daily for 52 weeks. If efficacy was insufficient at week 8, the dose could be increased to 100 mg. Safety was evaluated based on vital signs, adverse events (AEs), laboratory findings, electrocardiogram and post-void residual volume...
January 2017: Lower Urinary Tract Symptoms
https://www.readbyqxmd.com/read/28117002/b3-adrenoceptor-control-of-lower-gen%C3%A4-tour%C3%A4-nary-tract-organs-and-funct%C3%A4-on-in-male-an-overv%C3%A4-ew
#8
Ecem Kaya, Suresh C Sikka, Didem Yilmaz Oral, Isil Ozakca, Serap Gur
BACKGROUND: The sympathetic nervous system is one component of the nervous regulatory system of the physiological function of the lower genitourinary tract. Our knowledge on the role of this sympathetic system has advanced during the last decade due to the characterization of b3-adrenoceptors (b3-ARs) in the urogenital system. OBJECTIVE: This review focuses on the pharmacological and molecular evidence supporting the functional roles of β3-AR in male genitourinary tissues of various species...
January 20, 2017: Current Drug Targets
https://www.readbyqxmd.com/read/28073038/persistence-in-the-treatment-of-overactive-bladder-syndrome-oab-with-mirabegron-in-a-multicenter-clinical-study
#9
Alois Martan, Jaromir Masata, Jan Krhut, Roman Zachoval, Tomas Hanus, Kamil Svabik
OBJECTIVE: The objective of this project was to evaluate treatment persistence in patients being treated for overactive bladder syndrome (OAB) with mirabegron, employing clinical follow-up in a prospective, multicenter study. STUDY DESIGN: This is an analysis of patients who started treatment with mirabegron between May and September 2014 and were evaluated 1year after treatment commenced. During this evaluation we determined how many patients stopped treatment and established their reasons for discontinuation...
December 23, 2016: European Journal of Obstetrics, Gynecology, and Reproductive Biology
https://www.readbyqxmd.com/read/28042309/the-link-between-vascular-dysfunction-bladder-ischemia-and-aging-bladder-dysfunction
#10
REVIEW
Karl-Erik Andersson, Donna B Boedtkjer, Axel Forman
The vascular supply to the human bladder is derived mainly from the superior and inferior vesical arteries, the latter being directly connected to the internal iliac artery. Aging is associated with an impairment of blood vessel function and changes may occur in the vasculature at the molecular, cellular and functional level. Pelvic arterial insufficiency may play an important role in the development of bladder dysfunctions such as detrusor overactivity (DO) and the overactive bladder syndrome. Chronic ischemia-related bladder dysfunction may progress to bladder underactivity and it would be desirable to treat not only lower urinary tract symptoms (LUTS) induced by chronic ischemia, but also the progression of the morphological bladder changes...
January 2017: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/28035527/new-and-emerging-therapies-and-targets-beta-3-agonists
#11
Lauriane Y M Michel, Jean-Luc Balligand
While crucial for the acute physiologic response to stress, the adrenergic system may become maladaptive upon prolonged stimulation in the course of development of heart failure. This has been the basis for the development of beta-blocking therapies, targeting mainly beta1-2 adrenoreceptors (B1-2AR). The third isotype, B3AR, was more recently identified in cardiac myocytes and endothelial cells from human (and many other animal species), where its distinctive coupling to nitric oxide and antioxidant pathways suggested potential protective properties that were unexploited so far...
December 30, 2016: Handbook of Experimental Pharmacology
https://www.readbyqxmd.com/read/28025920/impact-of-overactive-bladder-step-therapy-policies-on-medication-utilization-and-expenditures-among-treated-medicare-members
#12
Ibrahim M Abbass, Eleanor O Caplan, Daniel B Ng, Rita Kristy, Carol R Schermer, Pamela Bradt, Jenna M Collins, Wai Man Maria Chan, Brandon T Suehs
BACKGROUND: The impact of formulary management strategies on utilization and expenditures in overactive bladder (OAB) treatment has not been extensively investigated. In 2013, step therapy (ST) policies for 2 branded OAB treatments, mirabegron and fesoterodine, were removed from Humana Medicare Advantage Prescription Drug (MAPD) plans and Medicare prescription drug plans (PDP), allowing for an examination of the effect of ST policies on OAB medication use patterns and costs. OBJECTIVE: To assess the impact of removal of formulary restriction policies for mirabegron and fesoterodine on medication utilization patterns and costs associated with OAB treatment in Medicare patients...
January 2017: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/28009939/comparative-efficacy-and-tolerability-of-antimuscarinic-agents-and-the-selective-%C3%AE-3-adrenoceptor-agonist-mirabegron-for-the-treatment-of-overactive-bladder-which-is-more-preferable-as-an-initial-treatment
#13
Minoru Kobayashi, Akinori Nukui, Takao Kamai
OBJECTIVES: The objective of the present study was to evaluate comparative efficacy and tolerability of antimuscarinics and mirabegron as primary and salvage therapy in patients with overactive bladder (OAB). METHODS: Patients ≥50 years with OAB symptoms were enrolled. Patients were initially treated with antimuscrinics or mirabegron for 8 weeks. When patients were refractory or intolerant to an initial treatment, drugs were switched to the other. The initial and second-line efficacy was assessed at baseline, 4 and 8 weeks after the treatment having the following parameters of the International Prostatic Symptom Score (IPSS), quality of life (QOL) index, Overactive Bladder Symptom Score (OABSS) and post-void residual (PVR) urine volume...
December 23, 2016: Lower Urinary Tract Symptoms
https://www.readbyqxmd.com/read/28001447/mirabegron-for-the-treatment-of-overactive-bladder-a-review-of-efficacy-safety-and-tolerability-with-a-focus-on-male-elderly-and-antimuscarinic-poor-responder-populations-and-patients-with-oab-in-asia
#14
Christopher R Chapple, Emad Siddiqui
Mirabegron is established as an alternative monotherapy to antimuscarinics for the treatment of overactive bladder (OAB) symptoms. Initial studies focused on Western populations, but over the past few years other populations and subpopulations have been evaluated. Areas covered: The authors' knowledge of the literature was used to develop the manuscript alongside a PubMed search ('mirabegron and clinical trial' and 'overactive bladder') to select independent studies of mirabegron. Up-to-date information is provided about the most recent mirabegron clinical trial and real-world efficacy, safety and tolerability data in a variety of patient populations with OAB, including those from different geographic areas, men, the elderly, and those with poor tolerability to antimuscarinics...
February 2017: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/27990717/the-first-in-man-randomized-trial-of-a-beta3-adrenoceptor-agonist-in-chronic-heart-failure-the-beat-hf-trial
#15
Henning Bundgaard, Anna Axelsson, Jakob Hartvig Thomsen, Mathias Sørgaard, Klaus F Kofoed, Rasmus Hasselbalch, Natasha A S Fry, Nana Valeur, Søren Boesgaard, Finn Gustafsson, Lars Køber, Kasper Iversen, Helge H Rasmussen
AIMS: The third isotype of beta adrenergic receptors (β3 ARs) has distinctly different effects on cardiomyocytes compared with β1 and β2 ARs. Stimulation of β3 ARs may reduce cardiomyocyte Na(+) overload and reduce oxidative stress in heart failure (HF). We examined if treatment with the β3 AR agonist mirabegron increases LVEF in patients with HF. METHODS AND RESULTS: In a double-blind trial we randomly assigned 70 patients with NYHA class II-III HF and LVEF <40% at screening-echocardiography to receive mirabegron or placebo for 6 months as add-on to optimized standard therapy...
December 18, 2016: European Journal of Heart Failure
https://www.readbyqxmd.com/read/27972922/cost-effectiveness-of-overactive-bladder-treatment-with-mirabegron-in-patients-in-south-korea
#16
D Suh, S Lee, S J Lim, J Song, G Ko
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27971353/estimating-the-economic-and-clinical-benefits-of-mirabegron-versus-antimuscarinics-for-the-treatment-of-overactive-bladder-oab-in-the-united-kingdom-uk
#17
J Nazir, M Berling, C McCrea, F Fatoye, Z Hakimi, A Wagg
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27942790/is-mirabegron-equally-as-effective-when-used-as-first-or-second-line-therapy-in-women-with-overactive-bladder
#18
Maurizio Serati, Umberto Leone Roberti Maggiore, Paola Sorice, Simona Cantaluppi, Enrico Finazzi Agrò, Fabio Ghezzi
INTRODUCTION AND HYPOTHESIS: No previous studies have investigated the efficacy of mirabegron 50 mg as the first-line therapy in OAB patients. Hence, the primary objective of this study was to evaluate the efficacy of mirabegron in treatment-naive patients in comparison with those who had discontinued antimuscarinic therapy because of insufficient efficacy. METHODS: All consecutive women who had pure OAB symptoms (including urgency with or without urgency incontinence and frequency) for at least 3 months were considered for this study...
December 10, 2016: International Urogynecology Journal
https://www.readbyqxmd.com/read/27914999/dual-therapy-for-refractory-overactive-bladder-in-children-a%C3%A2-prospective-open-label-study
#19
Fannie Morin, Anne-Sophie Blais, Geneviève Nadeau, Katherine Moore, Lucie Genois, Stéphane Bolduc
PURPOSE: Mirabegron (β3 adrenoreceptor agonist) is a new molecule with a mechanism of action distinct from antimuscarinics. Combination therapy with solifenacin was recently studied in an adult population. We evaluated the efficacy and safety of mirabegron as add-on therapy to treat urinary incontinence in children with idiopathic overactive bladder refractory/intolerant to antimuscarinics. MATERIALS AND METHODS: A prospective off-label study using add-on regimens of mirabegron was conducted in pediatric patients presenting with no symptom improvement while undergoing intensive behavioral and medical therapies and/or significant side effects while undergoing antimuscarinic dose escalation...
November 30, 2016: Journal of Urology
https://www.readbyqxmd.com/read/27911988/long-term-persistence-with-mirabegron-versus-solifenacin-in-women-with-overactive-bladder-prospective-randomized-trial
#20
Manami Kinjo, Yuki Sekiguchi, Yasukuni Yoshimura, Kikuo Nutahara
OBJECTIVES: To compare persistence with medication and the reasons for discontinuation of mirabegron or solifenacin therapy up to12 months in women with overactive bladder (OAB). METHODS: Female OAB patients who presented to women's urology clinics were enrolled in a prospective, randomized, two-arm study. Patients were randomized to receive mirabegron at 25-50 mg (n = 76) or solifenacin at 2.5-5 mg (n = 72). The persistence rate and the reasons for discontinuation were investigated up to 12 months...
December 2, 2016: Lower Urinary Tract Symptoms
keyword
keyword
7718
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"